PP
ATRS

PDT Partners’s Antares Pharma, Inc. ATRS Stock Holding History

PDT Partners’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-17,086
Closed -$74K – 970
2021
Q2 		$74K Sell
17,086
-27,649
-62% -$113K ﹤0.01% 770
2021
Q1 		$184K Buy
+44,735
New +$194K 0.01% 708

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
Amundi
Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

PDT Partners's ATRS Position: Q3 2021 in Review

PDT Partners sold out of Antares Pharma, Inc. (ATRS) in Q3 2021, closing a stake of 17,086 shares — an estimated $74K sold.

PDT Partners first reported a position in ATRS in Q1 2021 and held it in 2 quarters. The position peaked at $184K in Q1 2021. 170 funds tracked by Wall St. Rank hold ATRS as of Q3 2021.

  • PDT Partners reported no remaining Antares Pharma, Inc. position as of Q3 2021 after selling out during the quarter.
  • PDT Partners sold 17,086 Antares Pharma, Inc. shares in Q3 2021, an estimated $74K.
  • PDT Partners first reported a position in Antares Pharma, Inc. in Q1 2021 and held it in 2 quarters.
  • PDT Partners's Antares Pharma, Inc. position peaked at $184K in Q1 2021.
  • 170 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2021.

Based on PDT Partners's 13F filing for Q3 2021, filed 15 Nov 2021.